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Objective: To assess the incidence and severity of adverse-effects of long-term low-
dose glucocorticoid therapy in rheumatoid arthritis. 
Materials and methods: We reviewed the literature of clinical trials and physiological 
studies evaluating adverse effects of glucocorticoids. In addition, safety data from four 
prospective, randomised, placebo-controlled clinical trials of two years duration 
evaluating the effect of low-dose glucocorticoids (≤10mg prednisone equivalent per day) 
in patients with mainly active, early rheumatoid arthritis was evaluated. Results from the 
COBRA trial, which used higher doses for a short period of time, followed by 5 months 
low dose, are also analysed. 
Results: Adverse-effects of glucocorticoids are abundantly referred to in literature. 
However, in the available literature on low-dose glucocorticoid therapy very little of the 
commonly held beliefs about their incidence, prevalence and impact of GC proved to be 
supported by clear scientific evidence. Additional data from the randomised controlled 
clinical trials reviewed showed that the incidence, severity and impact of adverse effects 
of low dose glucocorticoid therapy in rheumatoid arthritis trials are modest, and often 
not statistically different to those of placebo. 
Conclusions: Probably many of the well known adverse effects of glucocorticoids are 
predominantly associated with high dose treatment. Given the lack of sound evidence, 
the use of low-dose glucocorticoids in rheumatoid arthritis merits reconsideration, 
weighing the risks and benefits. Further studies designed to address safety of chronic 
low-dose glucocorticoid treatment in rheumatoid arthritis are warranted to establish the 
true incidence, severity and impact of adverse-effects. 
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Introduction 
The introduction of glucocorticoids in the 1950’s has been a revolution in the treatment 
of a large variety of inflammatory diseases. Enthusiasm generated by the dramatic 
results led to the use of high doses, which revealed a spectrum of toxicity that shook the 
foundations of this therapy. Despite this, glucocorticoids (GC) still play a pivotal role in 
the management of diverse rheumatic conditions. The proportion of patients treated with 
GC by practicing physicians on a daily basis is clearly in excess of the usually 
conservative recommendations in textbooks and review papers. Recent studies 
demonstrating the disease modifying potential of GC in lower dosages in rheumatoid 
arthritis (RA) have renewed the debate on risk/benefit ratios with this therapy. 
Arguments against GC use are dominated by fear of a toxicity spectrum that is well 
engraved in international medical culture but which is strongly influenced by 
observations derived from the use of high doses of GC. Whether these fears are 
justified in relation to lower dose therapy, specifically for patients with RA, remains 
incompletely answered. 
To address this problem, a working party was organized, comprising experts with a 
special interest in this area, including rheumatologists and one endocrinologist from 
Europe and the U.S.A. with representation of most groups that have conducted 
randomised clinical trials on the use of GC in RA. The panel agreed to perform two 
major tasks of which the results are presented in this paper: 
1. A literature review of the adverse-effects of long-term low-dose GC especially in 
rheumatic diseases. The group composed an extensive and comprehensive list of all 
putative adverse-effects attributed to GC on a primary search of textbooks and 
review papers. This list was categorized in sections similar to those in this text. As a 
first step, for each category a thorough search was performed, using the adverse-
effects as key-words and the reference lists of the original papers. This literature was 
reviewed and described; the texts produced circulated numerous times among all 
members of the group for critical appraisal of completeness and balance. Given that 
the vast majority of available data on GC is observational and retrospective, 
regarding diverse diseases, dosages and regimes, appreciation of the level of 
evidence was frequently difficult and subjective. This then was resolved by reviewing 
the underlying data and discussion, until consensus was achieved. 
2. An analysis of toxicity data from the randomised controlled trials of GC in RA. As the 
working party comprised of representatives of all groups which conducted two-year 
trials on the use of GC in RA, very detailed information on adverse-effects from 
these trials was available for the discussions. Differences in methodology precluded 
a systemic meta-analysis of the adverse-effects observed. Here results from each 
trial, where available, are summed. Trials of which data is incorporated in this review 
include the Arthritis and Rheumatism Council low-dose glucocorticoid study, here 
further designed as ACR-study,1,2 the German study, here further designed as 
LDPT-study,3 the Utrecht study,4 and WOSERACT,5 see Table 1. Although the 
proposed definition of ‘low-dose’ is 7.5 mg prednisolone equivalent or less, to 
enhance readability these four trials as a group are in this paper designed as ‘the 
four extensively reviewed trials on low-dose GC in RA’. More details on these trials 
are available via hyperlinks to the electronic version of this article on the website of 
Annals of the Rheumatic Diseases (Hyperlink 1). Previously unpublished detailed 
monitoring results from the "combination therapy in early rheumatoid arthritis" 
(COBRA)-trial are included in the web version of this paper (Hyperlink 2). 
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This paper is the result of these efforts. It gives a critical and pragmatic overview of 
scientific evidence on the adverse effects of chronic GC therapy in lower dosages (10 
mg prednisolone equivalent or less) in RA in daily clinical practice. 
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Table 1. Characteristics of the four extensively reviewed rheumatoid arthritis trials using ≤10 mg prednisone daily 
 
Study ARC-study LDPT-study Utrecht study WOSERACT 
Year of publication 1995 2002 2002 2004 
Reference 1,2 3 4 5 
 
RA duration at entry < 2 years < 2 years <1 year median 12 months 
 
Number of patients,. 
 prednisolone group 61 34 40 84 
 
Prednisolone dose / day 7.5 mg 5 mg 10 mg 7 mg 
 
Duration of trial 2 years 2 years 2 years 2 years 
 




















Osteoporosis is a well established side effect of chronic GC use. The incidence of 
osteoporosis is time and dose dependent, but there is no consensus regarding a “safe” 
dose. Although some studies suggest that doses of 7.5 mg of prednisone per day or 
less are relatively safe, a longitudinal study observed an average loss of 9.5% from 
spinal trabecular bone over 20 weeks in patients exposed to 7.5 mg of prednisolone per 
day.6-8. Studies focused on low-dose therapy are relatively scarce, however. Further, it 
is important to recognize that in non-randomised studies, factors such as age, 
underlying disease, disease severity, co-medication and duration of treatment can lead 
to confounding by indication for GC, and may thus preclude definite conclusions. 
Alternate-day GC regimes have not been demonstrated to reduce bone loss.9,10
In 1997, an exhaustive literature search for all prospective studies found only 18 studies 
and 329 patients in which bone mass was studied prospectively while on GC treatment 
for any disease.11 An update of this review now includes almost 1200 patients.12 At a 
mean dose of almost 9 mg prednisone equivalent /day, the best estimate of bone loss 
overall in spine and hip (without bisphosphonate therapy) is 1.5% per year. Important 
positive predictive factors include starting dose and chronic usage; and in the spine, 
dose and lack of vitamin D supplementation. 
The consequences of this bone mass loss upon fracture rate proved to be quite 
significant. Though the underlying disease itself, such as RA may be associated with an 
increased incidence of osteoporosis or falls, the chronic use of GC further amplifies this 
increased risk by a factor 2.13,14 In a recent multicenter cross-sectional study, 205 
patients with RA who were receiving GC orally on a daily basis were compared with 205 
matched patients who did not receive GC. Vertebral deformities were found in 25% of 
patients on GC versus in 13% of controls. The occurrence of vertebral deformities was 
dose dependent.7
In a recent retrospective cohort study using the General Practice Research Database of 
the UK it was shown that the rate of clinical vertebral fractures increased by 55% for a 
dose of prednisolone of less than 2.5mg/d and by over 400% if the dose exceeded 7.5 
mg/day.15 Inflammatory disease activity has been shown to be an independent risk 
factor for osteoporosis, at least in RA. Disease activity leads to reduced physical activity 
and elevated levels of inflammatory cytokines, such as TNFα, which stimulate 
differentiation of osteoclasts both directly and indirectly via rank ligand (osteoclast 
differentiation factor) and thus to bone loss. It is, therefore, possible that GC in RA, 
leading to decreased disease activity, may cause less bone loss than they would have 
in the absence of inflammatory disease. Studies conflict as to whether cumulative dose 
is,8,16 or is not15,17 associated with the degree of bone loss. A recent study showed that 
the greatest increase in the risk of vertebral fractures induced by GC was observed in 
older postmenopausal women, age being a risk factor independent from BMD.18. On the 
other hand, it is quite likely that, like some studies suggested, fractures occur at less 
decreased BMD levels in GC-treated patients than in patients not treated with GC.19
Data from the four extensively reviewed trials on low-dose GC in RA show that BMD 
loss over 2 years of low dose prednisone was not significantly different from placebo 
(See hyperlink 1). The higher doses of prednisone used in the COBRA-study was 
associated with a higher BMD loss,20 but this did not reach statistical significance either 
(See Hyperlink 2). Fracture incidences were similar in both groups in the LTDP study.3 
Despite this, the Utrecht group found a double incidence of radiological vertebral 
fractures in the prednisone group, but this did not reach statistical significance.4
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Osteoporosis is probably the most common adverse effect of chronic low-dose GC but 
fortunately is preventable. Strategies for the prevention and treatment of GC-induced 
osteoporosis are well established and have been object of recent extensive 
reviews,19,21,22 and authoritative guidelines.23-25
 
Osteonecrosis 
Osteonecrosis (avascular necrosis of bone) has been, for a long time, considered an 
important consequence of high dose GC use. In a Japanese study of osteonecrosis of 
the femoral head, 35% of all cases were related to GC treatment.26 However, it is 
sometimes difficult to differentiate whether the treatment or the underlying disease is the 
cause, as some conditions, such as systemic lupus erythematosus (SLE), are 
associated with increased risk on osteonecrosis,27 especially in young patients with 
multi-organ involvement. This is one of the reasons why some authors question the 
evidence that GC are actually responsible for osteonecrosis.28 Although the occurrence 
of GC-related osteonecrosis seems to be dose-dependent, this might be confounded by 
the fact that higher dosages are related to more severe underlying disease and 
increased risk of osteonecrosis. One study reported osteonecrosis in 2.4% of patients 
receiving GC replacement therapy,29 but data on low-dose GC treatment is scarce and 
mostly anecdotal. At least in SLE, higher average dose may be a more important 
predictor of avascular necrosis of bone then cumulative dose.30. No case of avascular 
necrosis was observed in the four extensively reviewed trials on low-dose GC in RA nor 
in the COBRA-trial (See Hyperlink 1 and 2). 
Many crucial questions in this area remain unanswered, namely regarding the relevance 
of the dose, route of administration and duration of GC treatment, as well as the host 
factors that modulate the risk. In the meantime, it is generally accepted that in patients 
treated with low dosages of GC, osteonecrosis is very infrequent. Primary prevention is 
not really possible; awareness should be increased.31
 
Myopathy 
The most remarkable finding when searching the literature regarding this topic is the 
lack of data and proper studies. A recent review on this subject supports this 
contention.32 Based on the scarce information available and our own experience, we 
believe that myopathy is exceedingly rare with glucocorticoid doses below 7.5 mg 
prednisolone-equivalent daily. Chronic steroid myopathy is quite often suspected, but 
infrequently found and/or documented. The clinical picture can be difficult to distinguish 
from the effects of the underlying disease, especially in case of musculoskeletal 
conditions, such as myositis or inflammatory arthritis.33 On EMG examination there is an 
absence of spontaneous electrical activity; the serum aldolase and CK-level are normal, 
but creatinuria may be increased. These findings are considered suggestive of steroid 
myopathy.34 Diagnosis can be ascertained by muscle biopsy, showing atrophy of type II 
fibres, and absence of inflammation. There are no real prevention or individual risk 
factors to be valued; awareness will facilitate early recognition of this problem. No cases 
of myopathy were observed in the four extensively reviewed trials on low-dose GC in 
RA (hyperlink 1). 
 
Endocrine and metabolic adverse-effects 
 
Glucose intolerance and diabetes 
GC increase serum glucose levels via an increase in hepatic glucose production and 
changes in insulin production and resistance.35-40 In patients without pre-existing 
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abnormalities of glucose tolerance, GC will result in slightly increased fasting glucose 
levels and a more pronounced increase of postprandial values. The increment follows a 
similar pattern in diabetic patients but tends to be more pronounced in long-standing 
diabetes.41,42
Glucocorticoid-related hyperglycemia is dose-dependent. However, low-dose GC are 
not devoid of this effect. One case-control study suggested an increased risk (odds ratio 
1.8) for initiation of anti-hyperglycemic drugs during glucocorticoid therapy using 0.25-
2.5 prednisone equivalent per day.43. Hyperglycaemia can also be observed after intra-
articular GC.44 It is likely that subjects with risk factors for the development of diabetes 
mellitus, such as a family history of this disease, increasing age, obesity and previous 
gestational diabetes mellitus, are at increased risk to develop new-onset 
hyperglycaemia during GC therapy.41This is usually rapidly reversed upon GC 
cessation, but some patients will go on to develop persistent diabetes.45
Next to the average daily dose, the type of GC is of great importance. Dexamethasone 
is 30 times and prednisone 4 times as potent as hydrocortisone in the impairment of 
glucose metabolism46. The suggestion that deflazacort may be less prone to cause 
hyperglycaemia than prednisone must be questioned due to the probably inadequate 
correction for glucocorticoid potency.47
Data from the four extensively reviewed trials on low-dose GC in RA is quite reassuring 
in this respect: no cases of new-onset diabetes were observed in either of the studies. 
The Utrecht trial found the least favourable results:4 a significant increase in mean 
fasting glucose was seen in the prednisone group (from 5.1 (0.6) at baseline to 5.9 (1.9) 
mmol/l at 2 years, p= 0.01). However, even in this study, hyperglycemia, as defined by 
the World Health Organization, developed in only 2 patients in the prednisone group 
(n=40) and 1 in the placebo group (n=41), see hyperlink 1. 
There are no preventive measures apart from the use of lower doses of GC. Alternate–
day therapy is associated with alternate-day hyperglycaemia.48
In patients with insulin-dependent diabetes exposed to very high doses of GC after 
kidney transplantation, an insulin dose 58% higher than in those not receiving GC was 
necessary.49,50 We could find no studies on the specific effects of low-dose GC in 
diabetic patients. A relevant and detailed discussion of glucose control under GC 
treatment has been published.42
 
Fat redistribution and body weight 
One of the most notable effects of chronic endogenous and exogenous GC excess is 
the redistribution of body fat. Centripetal fat accumulation with sparing of the extremities 
is a characteristic feature of patients exposed to long-term high GC dose. It is seen 
even with low-dose GC. Potential mechanisms include hyperinsulinemia, changes in 
expression and activity of adipocyte-derived hormones and cytokines, such as leptin 
and TNF-α, increased food intake (GC increase appetite) and muscle atrophy.51-55
Our own review of toxicity data from the four RA prospective trials shows that low-dose 
prednisone is associated with an increase of mean body weight over two years, in the 
range of 4 to 8%. In two of these trials, this weight gain was significantly higher than in 
the placebo group3,4  These observations were confirmed in the COBRA trial but the 
differences were nullified after prednisone was stopped. However, also patients in the 
control groups gained weight (hyperlink 1 & 2). 
 
Suppression of sex hormones secretion 
GC in high doses decrease gonadotropin-releasing hormone (GnRH) secretion from the 
hypothalamus, decrease basal and GnRH-stimulated LH secretion from the pituitary 
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and decrease the responsiveness of gonadal cells to LH, leading to lower levels of 
estrogens56 and testosterone.57,58 This latter effect predominates in males.59 These 
suppressing effects can contribute to steroid-induced osteoporosis. Despite these 
observations, it has been suggested that glucocorticoid therapy in rheumatic diseases 
does not cause a clinically relevant adverse effect on fertility,60 and decreased libido 
has not been reported as a common complaint in patients exposed to low-dose GC. In 





Dyslipidemia, atherosclerosis and cardiovascular disease 
GC treatment is considered to be a risk factor for dyslipidemia and atherosclerosis.61-64 
Several studies in SLE patients suggest that GC therapy is associated with 
hypercholesterolemia, in a dose-dependent way: significant changes were seen only at 
prednisone doses higher than 10 mg/day.65-67 Beyond induction of dyslipidemia, the role 
of GC in actual atherosclerosis is controversial. Longer steroid use is significantly 
associated with coronary artery disease in SLE patients.68-70 Also a study in RA patients 
suggested that GC treatment early in the disease course increased risk for coronary 
artery disease.71 On the other hand, in a study using an animal model of 
atherosclerosis,72 although administration of dexamethasone induced hyperlipidemia, it 
also reduced aortic plaque formation, an effect attributed to inhibition of infiltration of 
inflammatory and foam cells in the plaques. The recognition of an association between 
elevated C-reactive protein and accelerated coronary artery disease offers a theoretical 
basis for glucocorticoid benefit on atherosclerotic disease in the context of inflammatory 
diseases.73 Furthermore, recent data from cohorts show that RA disease activity 
unfavourably alters the blood lipid profile, and treatment (including GC treatment) can 
reverse these changes.74 In the four extensively reviewed trials on low-dose GC 
treatment in RA, lipids were not routinely assessed. 
Recently, a record linkage database study on 68781 GC-users (of whom 1115 patients 
with RA) and 82202 nonusers was published.75 The incidence of all cardiovascular 
diseases, including myocardial infarction, heart failure and cerebrovascular disease was 
not increased in patients using < 7.5 mg prednisolone on a chronic basis. However, it 
was increased in patients using dosages ≥ 7.5 mg daily: relative risk adjusted for all 
known risk factors 2.6, 95% confidence interval 2.2 to 3. In the four extensively 
reviewed trials on low-dose GC treatment in RA and in the COBRA trial, no excess 
cardiovascular events were reported, but the trial duration of 2 years was relatively short 
for development of these complications. 
In summary, evidence doesn’t support a significant role of low-dose GC treatment to the 
development of cardiovascular disease in RA, in contrast to higher dosages. In patients 
on low-dose GC, the disease itself seems to be a greater risk factor. 
 
Water and electrolyte balance, oedema, renal and heart function 
Hypernatremia, hypokalemia and sodium and water retention are mineralocorticoid 
effects, produced by endogenous GC at supraphysiologic concentrations.76 These 
effects may lead to oedema and contribute to hypertension and heart failure in patients 
with Cushing’s disease. However, synthetic GC (prednisone, prednisolone, 
methylprednisolone, dexamethasone) have little mineralocorticoid effects, and their 
administration increases glomerular filtration rate and induces kaliuresis and natriuresis 
without any change in plasma volume.77-86 A small number of trials have evaluated 
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chronic GC administration in moderate to high doses in patients with heart failure, and 
no significant detrimental effect on heart function emerged from these studies.87,88 In the 
four extensively reviewed trials on low-dose GC treatment in RA as well as in the 
COBRA trial, no cardiac insufficiency attributable to GC occurred. 
 
Hypertension 
Induction of hypertension is a well demonstrated adverse effect of GC, observed in 
about 20% of patients exposed to exogenous GC.89 The mechanisms involved have not 
been fully elucidated.90  A retrospective study of 195 patients with RA or asthma 
undergoing glucocorticoid therapy with less than 20 mg/day of prednisone for longer 
than a year,91 did not show any correlation between dose or duration of GC treatment 
and rise in blood pressure. 
Toxicity data from the four extensively reviewed trials on low-dose GC in RA is very 
reassuring in respect to blood pressure: there were no significant effects of prednisone 
upon blood pressure in any of the trials. During the first phase of the COBRA trial, while 
high to intermediate doses of GC were used, the mean blood pressure was at some 
points in time higher in the prednisone than in the placebo group. Note that patients with 
severe hypertension were excluded from most of these trials (hyperlink 1 & 2). 
These results suggest that glucocorticoid-induced hypertension is dose-related and is 
less likely with medium or low-dose therapy. Individual variation in susceptibility and 
other factors, such as the level of starting blood pressure, diet salt, functional renal 
mass, associated diseases and drug therapy may play a role in the development of 
glucocorticoid-induced hypertension.89 Some authors suggest that the use of alternate-
day regimens may reduce the tendency towards blood pressure increase,92 but 
evidence for this is weak. 
 
Other cardiac adverse-effects 
Incidences of arrhythmia 93 and sudden death are very rare and mostly limited to  
patients receiving high-dose pulse GC.94,95 In the four extensively reviewed trials on 
low-dose GC treatment in RA and in the COBRA trial, these events were not reported. 
 
Dermatological adverse-effects 
Clinically relevant adverse-effects on the skin include iatrogenic Cushing’s syndrome, 
catabolic effects (cutaneous atrophy, purpura, striae, easy bruisability and impaired 
wound healing), steroid acne and hair effects.96 Cushingoid phenotype is observed in 
over 5% of the patients exposed to ≥ 5 mg prednisone equivalent for ≥ 1 year.97-99 
Incidence of iatrogenic Cushing’s syndrome is dose-dependent and in general becomes 
evident after at least one month of glucocorticoid therapy.96 Some authors suggest that 
alternate-day administration decreases the development of cushingoid features,100 but 
this has not been clearly established. 
Catabolic effects on the skin may appear during local and systemic GC therapy. 
Cutaneous atrophy mainly result from the effect of GC on keratinocytes and fibroblasts. 
Decreased vascular structural integrity is probably a key determinant of purpura and 
easy bruisability in GC treated patients.101 These effects were reported to affect over 
5% of those exposed to ≥ 5 mg prednisone equivalent for ≥ 1 year.97,102,103 Wound 
healing impairment seems uncommon at low-dose, but there are no exact data on 
prevalence. There is no data on incidence of steroid acne and hair effects like hirsutism 
and hair loss, but they are more frequent with long-term treatment with moderate to high 
doses of GC, as after organ transplantation.96 These effects of GC may sometimes be 
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difficult to separate from those of the disease itself (e.g. hair loss in SLE) and other 
medications. 
Most of the cutaneous adverse-effects of GC are not serious for the doctor, but they 
may represent a very significant cosmetic problem for the patient. Available data 
suggest these effects are relatively uncommon and of minor clinical concern with low-
dose GC treatment, although data on incidence is scarce. There is no strong evidence 
to support the claim that use of the lowest possible dose and alternate-day therapy may 
fully prevent these adverse-effects to occur. In the four extensively reviewed trials on 
low-dose GC treatment in RA and in the COBRA study, serious cutaneous adverse-
effects were not reported, but trial duration was relatively short for development of these 
complications. 
 
Ophthalmologic adverse effects 
 
Cataract 
Long-term use of systemic GC may induce formation of posterior sub-capsular cataract, 
characterized by disruption of the ordered maturation of the lens fibres, which then 
accumulate on the front surface of the posterior lens capsule. Cortical cataracts have 
also been attributed to GC.104
Reports on the frequency of cataract with long-term low dose systemic GC therapy are 
scarce. In a group of RA patients treated with 5 to 15 mg/day of prednisone, mean 6 
(SD 3) mg for a mean of 6 (SD 5) years, 15% were found to have cataracts, compared 
with 4.5% of matched RA controls not using prednisone.14 There is no evidence that 
alternate-day therapy reduces the risk.105 Cataract formation is considered to be 
irreversible. We could find no evidence regarding the possibility of halting progression 
with dose reduction or treatment interruption. More careful prospective assessment of 
cataract formation among GC-users is needed to definitively address this question. In 
the four extensively reviewed trials on low-dose GC treatment in RA and in the COBRA 
study, excess cataracts were not reported, but trial duration was probably too short for 
development of this complication and only two of the four extensively reviewed trials on 
low-dose GC treatment in RA included a regular ophthalmologic check in a significant 
number of patients. 
 
Glaucoma 
Systemic GC increase the risk of glaucoma and may result in visual field loss or even 
blindness. In the general population, 18 to 36% of those exposed to GC experience an 
increase in intraocular pressure.106 Open-angle glaucoma was found in 6 patients out of 
32 rheumatic patients exposed to ≥7.5 mg of prednisone equivalent for more than a 
year (19%) and in 1 out of 38 treated with <7.5 mg of prednisone equivalent (2.6% - 
Tryc A, Bartholome,B, Buttgereit F, et al., unpublished data). 
However, the occurrence and magnitude of elevation of intraocular pressure with GC 
administration is highly variable between individuals.107. High frequency of this adverse-
effect on GC tends to occur in families, suggesting a genetic basis.108 Patients with pre-
existing glaucoma are especially sensitive: 46-92% of patients with open-angle and 
65% of those with closed-angle glaucoma will have this condition aggravated upon 
exposure to GC.106,109 Patients with diabetes mellitus, high myopia and relatives of 
those with open-angle glaucoma are reported to be more vulnerable to GC-induced 
glaucoma106. Elevation of intraocular pressure with exogenous GC is generally 
reversible upon cessation, although it may take several weeks. Medications that lower 
intraocular pressure may control even a significant pressure increase induced by 
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concomitant GC.110 As glaucoma often is asymptomatic and can lead to severe loss of 
sight, regular eye pressure checks seem thus recommendable for patients on high dose 
long-term systemic GC treatment, especially for those with associated risk factors for 
glaucoma. For patients on low-dose GC-therapy and no additional risk factors for 
glaucoma, it is generally stated that routine checks seem not to be indicated. Only two 
of the four extensively reviewed trials on low-dose GC treatment in RA included a 
regular ophthalmologic check in a significant number of patients. However, these 




Peptic ulcer disease 
The association between GC use and the risk of peptic ulcer disease has been subject 
of extensive debate and contradictory evidence.111-113 The influence of the underlying 
disease on the risk of peptic ulceration is difficult to isolate. Piper et al performed a 
nested-control study including 1415 patients admitted to the hospital for gastroduodenal 
ulcer or haemorrhage and 7063 randomly selected controls from Medicaid.114 The 
overall estimated relative risk for peptic ulcer disease amongst current GC users was 
2.0 (95% CI: 1.3 – 3.0). However, this increased risk was nearly completely due to co-
therapy with NSAIDs: the risk for patients co-medicated with NSAIDs was 4.4 (95% CI: 
2.0 – 9.7), but for those receiving only GC there was no significant increase in risk: 1.1 
(95% CI: 0.5 – 2.1). In large scale studies based on the UK General Practice Research 
Database,115 the relative risk of upper G-I complications was 1.8 (95% CI, 1.3–2.4) for 
users of GC compared to non-users. The risk tended to be greater for higher GC doses 
but this trend was not statistically significant. The risk was shown to be more than 12 
times higher for concomitant users of both GC and NSAIDs, compared with non-users 
of either drug. Data from the four RA prospective trials and the COBRA study shows no 
increased incidence of upper GI ulcers and bleeds, but these events are relatively 
uncommon and may not be detected in these clinical trials with a relatively low number 
of participating patients (hyperlink 1). In patients treated with GC without concomitant 
use of NSAIDs there thus seems to be no indication for gastroprotective agents if there 
are no (other) risk factors for peptic complications. 
 
Pancreatitis 
Although GC are usually listed as one of the many potential causes of pancreatitis, 
evidence for such an association is weak and difficult to separate from the influence of 
the underlying disease, such as SLE or vasculitis. Experimental and post-mortem 
studies suggest that GC use is associated with increased incidence of pancreatitis. In 
one post-mortem study, acute pancreatitis or fat necrosis was observed in 29% of those 
treated with ACTH or GC vs 4% in the controls.116 However, none of these patients had 
been diagnosed with pancreatitis premortem, suggesting that clinically relevant 
pancreatitis due to GC is rare. Controlled studies showed that GC treatment does not 
cause an increased incidence of pancreatitis in SLE patients.117 In the four extensively 
reviewed trials on low-dose GC treatment in RA and in the COBRA study, no case of 
pancreatitis was reported. 
 
Infectious adverse-effects 
The use of GC is associated with increased susceptibility to various viral, bacterial, 
fungal and parasitic infections. The mechanisms underlying this effect are manifold and 
not completely understood.118 Most of these mechanisms, such as the decrease in 
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function of monocytes, subside rapidly with treatment interruption, an observation that 
may explain the lower infectious risk with the use of short-acting GC and alternate day 
therapy.119,120 The risk of infection increases with dose and duration of treatment,121 and 
tends to remain low in patients exposed to low-doses, even with high cumulative 
dosages.122 In a meta-analysis of 71 trials involving over 2000 patients with different 
diseases and different dosages of GC, a relative risk of infection was found of 2.0.123 
Five of these 71 trials involved patients with rheumatic diseases and showed no 
increased relative risk. In two studies specifically on RA the incidence of serious 
infections was found to be similar to that of placebo or only slightly increased.4,14 SLE is 
associated with increased risk of opportunistic infections, exacerbated by therapy with 
GC.124,125 Of the intensively reviewed four studies of low-dose GC therapy in RA, both in 
the Utrecht and the Woseract trials, prednisone in up to 10mg/day was not associated 
with increased incidence of any kind of infections over the two years of the trials.4,5
In patients treated with GC, physicians should anticipate the risk of infections with both 
usual and unusual organisms, realizing that GC may blunt the classic clinical features 
and delay the diagnosis. Under special clinical circumstances and in severely immuno-
compromised patients it may be wise to screen for latent infections, such as 
tuberculosis, or institute prophylactic chemotherapy.122 Pneumocystis carinii infections 
deserve special attention, as doses as low as 16 mg per day of prednisone for eight 
weeks have been associated with increased risk in one series.126
 
Psychologic and behavioural disturbances  
 
Steroid psychosis 
Psychosis is characterized by hallucinations, delusions or both. Estimates of the 
incidence of steroid psychosis vary greatly in literature (0 - 60%), due to differences in 
study populations and methodology of assessing this adverse-event. Following an 
authoritative review, the estimate of incidence of 5 to 6% has become consensual in the 
literature.127 However, most cases are associated with high doses of GC and an 
influence of the underlying disease, such as SLE, is frequently difficult to exclude. A 
landmark study in this area is the Boston Cooperative Drug Surveillance Program.128 
The incidence of steroid psychosis in 718 prednisone treated patients was 1.3% at 40 
mg daily, 4-5% at 41 to 80 mg and over 18% with higher doses. Several studies 
regarding doses of 20mg or less did not find cases of psychosis.129 Nor in the four 
extensively reviewed trials on low-dose GC treatment in RA, nor in the COBRA-study, 
this adverse-event was reported. 
Thus the clinician should be aware of this adverse-effect  and its clinical features,130,131 
but overt psychosis is extremely rare with the low and medium dose regimes usually 
employed in rheumatology. 
 
Minor mood disturbances 
GC treatment has been associated with a variety of low-grade disturbances such as 
depressed or elated mood (euphoria), irritability or emotional lability, anxiety and 
insomnia, memory and cognition impairments. The exact incidence of such symptoms in 
rheumatic patients exposed to common doses of GC cannot be drawn from the 
literature. Most studies relate to doses of 80 to 160mg of prednisone equivalent per day, 
far exceeding common long-term regimes in rheumatology.132 Evidence regarding minor 
effects is scarce but doses of less than 20 to 25 mg prednisone equivalent are 
associated with few or no significant disturbances.133,134 However, individual 
susceptibility is highly variable and there are a few published cases where relationship 
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between low-dose GC and even topical steroids and psychotic episodes seems hard to 
doubt. In the four extensively reviewed trials on low-dose GC treatment in RA, nor in the 




Significant interactions between GC and other prescription therapies have been well 
documented. Drugs that reduce the systemic GC concentration may diminish clinical 
efficacy. They include large doses of aluminum/magnesium hydroxide, which decrease 
prednisone bioavailability by 30 to 40 percent,135,136 and most anticonvulsants (eg, 
phenobarbital, phenytoin), which enhance the metabolism of GC.137-142 Rifampin 
accelerates the metabolism of synthetic steroids as may St. John’s wort.143 Rifampin-
induced non-responsiveness to prednisone of inflammatory diseases has been 
described and rifampin-induced adrenal crisis in patients on GC replacement therapy 
has been documented.144-147
Drugs that raise the systemic GC concentration include some oral contraceptives,148-151 
antibiotics (erythromycin and troleandomycin).152-154 Antifungal agents, particularly 
ketoconazole decrease GC metabolising enzymes.155,156 Some data suggests that 
several NSAIDs, including indomethacin and naproxen, increase GC concentrations.157 
The other way round, GC may affect serum concentration, efficacy or toxicity of other 
drugs, such as warfarin and salicylates.158,159 In addition, when used concomitantly with 
traditional NSAIDs, GC cause an increased risk of upper gastrointestinal adverse 
events, particularly in patients with RA, see above.115,160
Nor the four extensively reviewed trials on low-dose GC treatment in RA, nor in the 
COBRA-study, were adequate to study these interactions. 
 
Conclusions and research agenda 
After a careful literature review of the adverse-effects of low-dose GC, extensive review 
of adverse-effects of four trials on low-dose GC treatment in RA and the COBRA study, 
and extensive group discussions, the authors’ main conclusion is that definitive 
associations of low-dose GC with many adverse-effects remain elusive. The overall fear 
of GC toxicity in RA, as quoted in textbooks and review articles, is probably 
overestimated based on extrapolation from observations with higher dose therapy. The 
balance of risks and benefits of low dose therapy clearly differs from that of medium and 
high dose therapy, of which the mechanisms of action of GC may be different.161This 
may explain why GC are used in practice in more patients than the more pessimist 
recommendations suggest. Physicians, and probably patients, seem to value the 
benefit/risk ratio of low-dose GC. There is surprisingly weak evidence on which to 
support clear recommendations about toxicity of low-dose GC. The literature and the 
recent trial results suggest that routine toxicity monitoring for patients on low-dose GC is 
not currently justifiable or cost effective based on existing evidence. However, patients 
with additional risk factors (e.g. osteoporosis, obesity, hypertension, family history of 
diabetes or glaucoma) merit more careful observation (Table 2). 
 
Table 2. Glucocorticoid related adverse-effects other than osteoporosis that may justify 
clinical control. 
• Cushingoid symptoms 
• Adrenal crisis on glucocorticoid withdrawal 
• Growth retardation in children 
• New onset of diabetes mellitus in subjects at risk for developing DM 
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• Worsening of glycemia control in patients with diabetes mellitus 
• Cataracts and glaucoma 




GC will likely retain an enormous therapeutic value in treatment of a large variety of 
rheumatic conditions for many years to come, especially since it becomes increasingly 
clear that they have disease modifying potential. The data reported in this paper of trials 
not primarily designed for assessment of adverse effects and of observational studies 
with possible bias, especially confounding by indication, do not represent the highest 
level of evidence. So safety of low-dose GC also needs to undergo serious and 
systematic re-evaluation with properly designed and dedicated studies of adequate size, 
duration, and utilizing state-of-the-art endpoints. Guidelines for such studies would 
enhance comprehensiveness and comparability. We believe the areas listed in Table 2 
should be further explored when new studies of low dose GC are to be undertaken, and 
physicians might wish to consider these issues in clinical practice when prescribing GC 
treatment. Furthermore, subjects participating in randomised clinical trials may not have 
the same disease characteristics or comorbidities of patients treated in the community, 
thereby limiting the generalizability of findings of this kind of trials.162 So, simple, 
pragmatic trials with appropriate patient selection and sufficiently long duration are also 
needed. 
Other areas of research include the best timing of administration, the potential 
advantages and limitations of alternate-day dosing, identification of risk factors for such 
adverse-effects as upper G-I complications, glaucoma, cataract, and studies of the 
individual sensitivity to GC related to underlying mechanisms, such as receptor gene 
polymorphisms.163 Elucidation of the biological mechanisms involved in these effects 
will open new opportunities for prevention and treatment. Research on the potential 
separation of wanted from unwanted GC effects using newly designed GC-type 
medicine provides good reason for hope that an even better safety/efficacy ratio can be 
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Toxicity data from four prospective trials of low-dose glucocorticoid therapy 
in R.A. 
 
Box 1. Description of Trials 
The ARC Low Dose Glucocorticoid Study (ARC)1;2.  
A double blind, randomised controlled trial over 2 years followed by 1 year double blind follow-up in 128 
patients with rheumatoid arthritis diagnosed for less than 2 years. Patients had active disease and were 
allocated equally to prednisolone 7.5mg daily (in specially prepared tablets) or placebo. All other 
treatments except oral glucocorticoids were permitted and in practice most patients were treated with 
non-steroidal anti-inflammatory agents and second line anti-rheumatoid treatment. 
The "Low-Dose Prednisolone Therapy"Study (LDPT)3.  
In this double blind study 192 patients with active rheumatoid arthritis of duration less than 2 years who 
had not been treated before with intramuscular gold or methotrexate were equally and randomly allocated 
to one of two treatment strategies for two years: 1) 5 mg prednisone once daily in the morning and either 
intramuscular gold (50 mg gold sodium thiomalate/week up to a total dose of 1000 mg, thereafter 50 mg 
every 2 weeks) or methotrexate (7.5 mg weekly for the first 3 weeks, thereafter 10-15 mg weekly; no 
folate supplementation) 2) placebo and intramuscular gold or methotrexate as above. Therapy with 
bisphosphonates, calcitonin, estrogens and fluorides was not allowed.  
The Utrecht Prednisolone Trial4.  
In this double blind study 81 patients with rheumatoid arthritis of duration less than 1 year were equally 
and randomly allocated to one of two groups of treatment for two years: 1) 10 mg prednisone once daily 
at breakfast, 2) placebo in the same way. NSAIDs and analgesics were permitted and all patients 
received 500 mg elementary calcium in the evening. After 6 months sulfasalazine rescue  
medication was permitted. 
The West of Scotland Early Rheumatoid Arthritis Trial (WOSERACT)5.  
In this double blind study 167 patients with rheumatoid arthritis of median disease duration 12 months 
(range 2-84 months) were equally and randomly allocated to one of two groups of treatment for two 
years: 1) 7 mg prednisolone once daily plus sulphasalazine (dose target 40mg/kg in both arms. Medians 
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achieved (and range): 2.5g (1-4g) in both arms)  2) placebo prednisolone and sulphasalazine. At 2 years, 
in the prednisolone group 61 patients were still on prednisolone and 59 patients still on sulphasalazine. In 
the placebo group at 2 years 65 patients were still on placebo prednisolone and 53 still on 
sulphasalazine. The use of drugs for prevention of osteoporosis was left to the discretion of the 
rheumatologist: it was greater in the active group, although physicians were blind to treatment.  
 
 




Box 2. Osteoporosis data from trials: Bone loss and fractures 
ARC  Results1;2.  
Results are available for 21 patients (Prednisolone=11, Placebo=10) who had bone mineral density 
(BMD) measurement because they were attending study centres where measurement facilities were 
readily available at the time of the study. Mean (SD) percentage reductions in BMD in the spine of the 
prednisolone group were 1.61 (4.98) and 2.96 (5.59) after 1 and 2 years respectively while in the placebo 
group the percentage reductions were 2.27 (5.54) and 1.29 (4.64) (not significantly different). In the hip 
the prednisolone group percentage reductions were 2.16 (7.07) and 1.19 (3.16) after 1 and 2 years 
respectively while in the placebo group the percentage reductions were 0.56 (5.62) and 4.02 (2.45) 
(P=0.04 at 2 years). 
LDPT Results3.  
X-rays of the lumbar spine among patients in prednisolone group (n=59) revealed two fractures at 
baseline, and one additional fracture at 24 months (n=46). Among patients (n=64) in the placebo-group, 
there were at baseline two fractures, and at 24 months (n=53) two additional fractures. The fractures 
were located at L1 (n=2), L2 (n=3) and L3 (n=2). 
Utrecht Results4.  
In the two years, T-scores mean (se) of the lumbar spine in the prednisone group changed from -0.8(0.3) 
to -1.1(0.3) and in the placebo group from -0.7(0.3) to -0.6(0.3). For the femoral neck T-scores changed 
from-1.8(0.2) to -1.9(0.2) and from -1.9(0.2) to -1.9(0.2), respectively. This were all non significant intra 
and between group differences. So, for the lumbar spine at 2 years, the difference between the T scores 
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of the two groups was 0,5 in favor of the placebo group; this was unchanged at follow-up at 3 years. At 3 
years, the cumulative number of fractures in the spine in the prednisone group was twice that of the 
placebo-group (10 versus 5). Doubling of the fracture rate has been described for changes in the T score 
of 1; this suggests that the double fracture rate in the prednisone group was also partly due to structural 
changes of bone in the prednisone group. 
WOSERACT Results5.  
In the 2 years, median lumbar bone density in the prednisolone group changed from 1.079 at baseline to 
1.073 g/cm2; in the placebo group bone densities were 1.157 and 1.280 g/cm2, respectively. For the 
femoral neck, bone density in the 2 years changed from 0.900 to 0.881 g/cm2 in the prednisolone group 
and from 0.927 to 0.911 in the placebo group. There were no statistically significant differences between 
the two groups at both points in time, nor statistically significant changes within groups. 
 
 
Endocrine and metabolic adverse effects 
 
Glucose intolerance and diabetes 
 
Box 3. Hyperglycaemia data from the trials: blood and urine glucose levels 
ARC Results1;2.   
No patient in the prednisolone group (n=61) developed diabetes mellitus, but one patient in the placebo 
group (n=67) did so. 
LDPT Results3.  
In the prednisolone group serum glucose levels of 34 patients (per protocol population) were measured 2 
hours after the last meal; at baseline and at 2 years, means (se) were the same: 5.6 (0.2) mmol/l. In the 
placebo group, mean (se) serum glucose levels of 42 patients (per protocol population) were 5.3 (0.2) at 
baseline and 5.1 (0.2) mmol/l at 2 years. In addition, the values for the so-called intention-to-treat 
population are given: prednisolone group (n=74): baseline value 5.7 (0.1) and after 24 months 5.6 (0.3) 
mmol/l, placebo-group (n=81): at baseline 5.9 (0.2) and at 24 months 5.5 (0.3) mmol/l. 
Utrecht Results4.  
In contrast to the placebo group, the mean (SD) serum glucose level increased significantly in the 
prednisone group, from 5.1 (0.6) at baseline to 5.9 (1.9) mmol/l at 2 years, p= 0.01. Hyperglycemia, as 
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defined by the World Health Organization, developed in 2 patients in the prednisone group (n=40) and 1 
in the placebo group (n=41). 
WOSERACT Results5.  
One patient in the placebo arm was on treatment for diabetes mellitus at the outset and 2 years. No 




Endocrine and metabolic adverse effects 
 
Fat redistribution, body weight and growth 
 
Box 4. Weight gain trial data 
 
ARC Results1;2.   
Both groups increased in weight, but there was no statistically significant mean increase in body weight in 
either group. One patient in the study had relevant weight gain; this patient had been allocated to 
prednisolone. 
LDPT Results3.  
Weight gain was assessed for the intention-to-treat population: 80 patients in the prednisolone group and 
85 patients in the placebo group. Body weight in the prednisolone group increased from a mean (se) of 
71.7 (1.4) kg at baseline to 76.7 (2.0) kg at 2 years, p<0.05; in the placebo group the numbers were 73.1 
(1.7) kg at baseline and 73.4 (2.3) kg at 2 years. The difference at two years between the two groups was 
statistically significant. 
Utrecht Results4.  
In the 10 mg prednisone group (trial methodology: see above) body weight increased significantly from 
baseline: the mean (sd) rose from 77 (19) to 80 (20) kg at 2 years, p=0.001; in the placebo group there 
was no statistically significant difference in time. 
WOSERACT Results5.  
In the 7 mg prednisolone group (trial methodology: see above), body weight increased from 68kg at year 
0 to 71kg at year 1 and 72kg at year 2 (Wilcoxon 0-1 year and 0-2 year p<0.001). In the placebo group 
weight increased from a median of 69kg at time 0 to 70kg at year 1 and 72kg at year 2 (Wilcoxon 0-1 year 
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p=0.162, 0-2 year p<0.05). There were no statistically significant differences between the two groups at 








Box 5. Hypertension data from Trials 
 
ARC Results1;2.   
On the group level: there were no significant increases in blood pressure in either group. On the patients' 
level: two patients in the prednisolone group (n=61) developed hypertension versus one patient in the 
placebo group (n67). 
LDPT Results3.  
At the start of the study, mean (se) blood pressure values (systolic/diastolic) were 128(2) / 79(2) mm Hg 
in the prednisone group (n=34) and 130(3) / 80(2) in the placebo group (n=42). At two years, these 
numbers were 141(4) / 85(2) and 140(4) / 86(2), respectively: no statistically significant differences 
between the two groups at both points in time, nor statistically significant changes within the groups. For 
the intention-to-treat population (prednisolone group n = 80 and placebo group n = 85) the data were as 
follows. Prednisolone group baseline values:128(2) / 78(1); at 24 months 141(3) / 84(2). Placebo-group 
baseline values 128(2) / 79(1); at 24 months 140(4) / 85(2). In the prednisolone group 6 patients (6%) 
developed hypertension (as stated by the physician) compared to 2 patients (2%) in the placebo group. 
Utrecht Results4.  
Patients with severe hypertension were excluded from this study. At the start of the study 11 patients in 
the placebo group and 5 in the prednisone group were normotensive under medication for their essential 
hypertension and they remained stable during the study. The numbers of patients with newly developed 
hypertension during the study were about equal: 7 in the prednisone group and 6 in the placebo group.  
WOSERACT Results5.  
At the start of the study, median blood pressure values (systolic/diastolic) were 140/80 mm Hg in the 
prednisone group and 135/80 in the placebo group. At two years, these numbers were 140/80 and 
130/80, respectively: no statistically significant differences between the two groups at both points in time, 
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nor statistically significant changes within the groups. However, the participating rheumatologists were 
proactive in initiating antihypertensives as required and more patients were on antihypertensives in both 
the placebo and active groups than at the outset of the study (placebo 12 time 0, 16 at 2 years; active 10 
time 0, 13 at 2 years). 
 
 
Ophthalmological adverse effects 
 
Box 6. Ophthalmological data from Trials 
LDPT Results3.  
In the prednisolone group, 3 patients got glaucoma versus no patient in the placebo group; in the 
prednisolone group, 5 patient acquired cataract versus 6 patients in the placebo group; in both groups, 
less than 50% of patients was screened for ophthalmologic adverse effects, however. 
Utrecht Results4.  
 
In the prednisone group, 1 patient got glaucoma versus no patient in the placebo group; in both groups, 1 
patient acquired cataract. 
 
 
Gastrointestinal adverse effects  
 
Box 7. Gastrointestinal data from Trials 
ARC Results1;2.   
No patient with relevant peptic ulcer disease was reported. 
LDPT Results3.  
In this study, patients with recent gastric and intestinal ulcers were excluded. Gastric distress was seen in 
the prednisolone group (n=93) in 9 patients (10%), versus in 4 patients (4%) in the placebo group. A 
gastric ulcer was detected in 3 patients in the prednisolone group (3%), but in none of the patients in the 
placebo group. 
So, a higher rate of peptic ulceration and their complications due to low to medium dose glucocorticoids is 
not supported by these data. 
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Utrecht Results4.  
In the prednisone group, peptic symptoms leading to gastroscopy occurred in 7 patients versus 3 in the 
placebo group, but ulcer with bleeding at gastroscopy was found in 1 patient in the prednisone group 
versus 2 in the placebo group. 
WOSERACT Result5.  
One GI bleed occurred in the active steroid group, none in the placebo group. No other patient had 
relevant peptic ulcer disease. 
 
 
Infectious adverse effects 
 
Box 8. Infection trial data 
Utrecht Results4.  
Seventeen infections, treated with antibiotics occurred in 14 patients in the prednisone group (n=40) over 
the 2 years versus 22 infections treated with antibiotics in 15 patients in the placebo group (n=41). 
WOSERACT Results5.  
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Toxicity of Step-Down Glucocorticoid Therapy in the COBRA Trial 
(Authors of this section: Maarten Boers, Arco C. Verhoeven) 
 
Introduction 
The spectrum of toxicity of chronic glucocorticoid therapy is exhaustively reviewed in this 
article. However, less is known about the acute changes in routine monitoring parameters in 
patients with rheumatoid arthritis (RA). We reanalyzed the monitoring data of the COBRA trial 
that compared the combination of step-down prednisolone, low –dose methotrexate (MTX), and 
sulfasalazine (SSZ) to SSZ alone in early RA. This analysis demonstrates the highly consistent 
changes induced in many of these parameters, but also a relatively low yield in terms of findings 
requiring changes in therapy. 
Methods 
The COBRA (“COmbinatietherapie Bij Reumatoide Artritis”) trial was a multicenter 
randomized double-blind controlled trial of 56 weeks duration in patients with early active RA1. 
Application of the exclusion criteria resulted in a fairly healthy group (apart from the RA): we 
excluded patients aged below 18 or over 70, those with serious comorbidity or recent (3 months 
or less prior to inclusion) major surgery, with active infectious disease, with a history of 
tuberculosis, recurrent infections, recent (< 3 months) gastritis or gastrointestinal ulceration, any 
history of gastrointestinal bleeding or neoplasia. We also excluded patients with diabetes 
mellitus, hypertension treated with more than one antihypertensive drug, significant 
cardiovascular disease, liver disease, cataract, glaucoma, hematologic disorders, partial or total 
colectomy, reduced renal function (creatinine clearance < 50 ml/h), proteinuria (> 0.5 g/day), 
hypoalbuminemia and chronic dermatitis. Finally, we excluded patients on treatment with 
phenytoin, phenylbutazone, salicylates, barbiturates, cholestyramine, probenecid, oral 
anticoagulants (dicumarol derivatives), and patients with a history of alcohol or substance 
abuse1. 
COBRA treatment comprised a starting dose of prednisolone of 60 mg/day, rapidly tapered to 
7.5 mg/day within a time period of 6 weeks, continued unchanged for 20 weeks, and then 
withdrawn completely after 26 weeks; 2) a low dose of MTX (7.5mg/week in one gift) for 40 
weeks, and then withdrawn in 4 weeks; and 3) a maintenance dose of SSZ 2000 mg/day. All 
patients received folic acid supplements (1mg/day), and calcium supplements (500 mg daily); 
and/or vitamin-D supplements (25-(OH)-vitamin-D) (400 IE daily) were prescribed if necessary. 
Patients randomized to the SSZ monotherapy group received a maintenance dose SSZ (2000 
mg/day) as well as the supplements mentioned above. 
Monitoring schedule. Patients were seen weekly in the first four weeks; then at weeks 6, 9, and 
12; and every 4 weeks thereafter. At every visit patients were questioned for adverse events; 
body weight and blood pressure were recorded. Blood and urine samples were examined: more 
than 20 tests in total at 19 time points, i.e. almost 400 tests per patient in the 56 weeks of the trial 
(see results). Bone mass was measured every half year.  
Analysis. Results of monitoring per treatment group are presented as mean (95% confidence 
interval) in line graphs over time. The initial period is magnified to better depict the changes. To 
correct for baseline differences, body weight is expressed as change. In each graph, the “Null 
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Zone” indicates the area in which group means should fall if there is no significant difference at 
the 5% level (two-sided p value >0,05).2 In other words, observed means falling outside this 
zone differ significantly from each other. As these analyses are exploratory no correction for 
multiple testing was applied.  
Results 
Clinical results. The main findings of the COBRA trial have been published previously1. Briefly, 
COBRA treatment (76 patients) caused almost immediate and strong improvement in disease 
activity, resulting in similarly strong and significant functional improvement assessed at week 
16. Single treatment with sulfasalazine (79 patients) caused lesser but also significant 
improvement at week 16. Both treatment groups improved further up to week 28. Most of the 
clinical difference between the groups disappeared when prednisolone was subsequently 
withdrawn, with no further change after withdrawal of methotrexate. At week 28, the 
combination therapy group had significantly less progression of radiographic joint damage 
compared to the sulfasalazine group. Recently we have shown that progression remains slower in 
the COBRA group up to 4.5 years, i.e. 3.5 years after withdrawal of prednisolone.3
Toxicity. Significantly less patients stopped COBRA than sulphasalazine: 6 (8%) versus 23 
(29%) (p=0.0008), and COBRA patients dropped out later (Figure 1). Differences were apparent 
for both toxicity and lack of efficacy. For instance all 4 efficacy dropouts in the COBRA group 
occurred after week 28, when prednisolone and methotrexate were stopped; in contrast, most of 
the 19 dropouts in which loss of efficacy played a role in the sulphasalazine group occurred 
before week 28 (Figure 1). The adverse reactions that led to withdrawal of 2 patients in the 
COBRA group were: gastrointestinal tract complaints and dyspnea (final diagnosis exacerbation 
of chronic bronchitis). Adverse reactions that led to withdrawal of 8 patients in the 
sulphasalazine group were skin rashes in 4 patients, gastrointestinal tract complaints in 2 (one 
with concurrent proteinuria), granulopenia with concurrent increase in aminotransferases in one 
patient, and thrombopenia (diagnosis preleukemic disease) in the remaining patient.  
The study medication was discontinued and restarted at an adjusted dose according to protocol in 
5 patients. Three of these 5 patients (1 from the COBRA group) had low granulocyte counts, the 
other 2 patients (in the COBRA group) had elevated aminotransferases and gastrointestinal 
complaints, respectively. The remaining adverse events were not followed by withdrawal of 
study medication. These included 18 cases (12 COBRA) of infection, treated on an outpatient 
basis, 17 cases (9 COBRA) of gastrointestinal complaints (no ulcer or bleeding); 10 cases (6 
COBRA) of cardiovascular disease; including 1 myocardial infarction; and 11 cases (5 COBRA) 
of skin disorders. Various other symptoms, signs and transient laboratory abnormalities were 
reported in 37 cases (20 COBRA).(1) Thus, a total of about 62000 tests (400*155) not including 
confirmatory procedures were performed to detect relevant toxicity in a total of 7 patients. 
Bone mass. In the first 28 weeks, mean (95% c.i.) lumbar bone density change in the COBRA 
group (n=64) was –1.2% (-2.0,-0.3) versus 0% (-0.9, 0.9) in the sulphasalazine group (n=62) 
(p=0.06). In 56 weeks, changes were –1.3% (-2.3,-0.4) and –0.3% (-1.4, 0.8) respectively, 
p=0.15. In the femoral neck corresponding bone density changes over 28 weeks were –0.6 (-2.1, 
0.9) versus –0.7 (-2.1, 0.7); over 56 weeks –1.9 (-3.1,-0.7) versus –1,3 (-2.5,-0.1; both: p>0.2. 
Eight versus 6 patients lost more than 5% (mean 8%) of spinal bone; 14 versus 9 lost more than 
5% (mean 8%) of femoral neck bone. These losses typically occurred in the first half year, with 
stabilisation or improvement thereafter.(1)  
Diabetes. For this study, patients with concomitant diabetes mellitus were excluded. In all 
patients, regularly urinanalysis for glucose was performed; positive glucose reactions were 
extremely rare.  
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Weight. Only during the first half year of therapy, the COBRA treatment group in which high to 
intermediate doses of glucocorticoids were used gained statistically more weight than the 
sulphasalazine alone group. After about one year (56 weeks), the weight gain from baseline was 
1.7 kg in the combined treatment group (in which prednisone had been stopped) and 1.2 kg in the 
sulphasalazine alone group, a non-statistically significant difference. 
Upper GI. In the COBRA trial, patients with a history of gastrointestinal bleeding or recent (<3 
months) gastritis or gastrointestinal ulceration were excluded. In the COBRA strategy group and 
sulfasalazine alone group, gastrointestinal complaints occurred, probably at least due to 
sulfasalazine and/or methotrexate, but no ulcer or bleeding took place. A relevant finding from 
the economic study that ran alongside the trial: cost savings occurred because many patients in 
the COBRA group stopped taking NSAIDs and gastroprotection. 
The results of routine monitoring are shown in Figure 2 (blood pressure, weight gain, and 
selected blood chemistry) and Figure 3 (hematology). In Figure 2 ESR is shown as reference 
outcome measure for disease activity, and in both the prednisolone dosing schedule is shown at 
bottom. Apparent from almost all graphs is an almost immediate change in the COBRA group, 
followed by a slower change in the SSZ group. Within the groups the changes in many measures 
were highly consistent, resulting in strongly significant differences between the groups. These 
differences became less and mostly disappeared after the prednisolone was stopped, similar to 
the main outcome measures. Especially notable are the rapid (but limited) weight gain, the 
biphasic pattern in the platelet count, the rapid increase in hemoglobin and the increases in serum 
creatinine in both groups. More in line with expectation is the leukocytosis, granulocytosis, 
lympho– and eosinopenia. The changes in alkaline phosphatase are mainly attributed to changes 
in bone turnover, as there were no relevant changes in the liver function tests 
(gammaglutaryltransferase [GGT] stable; aspartate– and alanine aminotrasferase [ASAT and 
ALAT] decreased resp. increased slightly in the COBRA group in the first 6 weeks; data not 
shown). 
Discussion 
The results of the intensive monitoring schedule in the COBRA trial first of all confirm that RA 
causes profound disturbances in many physiologic parameters. The documented changes in the 
trial are the sum of (rapid or slow) improvement in disease activity with reversal of the 
abnormalities and specific effects of the drugs employed. In the first 4-8 weeks most changes are 
highly likely caused by the prednisolone dosing scheme. The biphasic platelet response in the 
COBRA group suggest an acute effect of platelet mobilization caused by prednisolone, followed 
by the antirheumatic effect which reverses thrombocytosis due to RA. It is less likely that an 
antirheumatic effect is the cause of the initial rapid increase in hemoglobin: reversal of anemia 
takes longer. Combined with the increases in creatinine it might be that RA itself causes changes 
in the distribution of intravascular fluid (i.e. hemodilution) which is reversed by therapy. 
The second observation is that in this relatively healthy population the monitoring schedule is 
fairly inefficient in detecting clinically relevant abnormalities. This is of course a well-known 
problem in the monitoring of antirheumatic therapy, and one that cannot be solved by 
observations from randomized trials. Both the selection of the patients and the relative rarity of 
severe adverse events make it difficult to extrapolate toxicity findings from trials to general 
practice. Nevertheless, most events that are amenable to detection by lab monitoring occurred in 
the initial phases of treatment. On the basis of the COBRA experience, we would now suggest a 
check of body weight, blood pressure and lab (hematology, creatinine, liver function tests; urine 
for glucose and protein, preferably 2 hours after a meal) at 1 and 3 weeks after the start of 
therapy. If these tests are normal, there is no necessity for further monitoring other than that 
 on 25 November 2005 ard.bmjjournals.comDownloaded from 
 4
advised for single DMARD therapy. It should be noted that recommendations for such 
monitoring is mostly based on expert opinion rather than evidence.  
In conclusion, early aggressive therapy of RA with step-down glucocorticoids according to the 
COBRA schedule causes rapid and highly consistent changes in blood pressure, body weight and 
lab parameters, contrasting with slower changes in patients treated with SSZ monotherapy. 
These changes are most likely the result of reversal of RA effects combined with intrinsic effects 
of the drugs in the combination, especially glucocorticoids.  
 
Legends 
Figure 1. Patients remaining in trial and reasons for dropout, per treatment arm.  
COBRA treatment protocol is shown at the bottom of the graph. AE, adverse event; LoE, loss of 
efficacy; viol, protocol violation. 
 
Figure 2. Line graphs of group means over time: ESR, mean blood pressure, weight gain 
and selected chemistry tests.  The gray area is the “Null Zone”, the area where the group means 
reside when there is no significant difference at the two-sided p of 0.05. The initial period is 
magnified to better depict the rapid changes in the first weeks. Each vertical grid line equals a 4-
week period. The thick grid lines show important changes in treatment schedule: end of step-
down prednisolone, start of tapering low dose prednisolone, start of methotrexate tapering.  
 
Figure 3. Line graphs of group means over time: hematology tests. 
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